Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Lexeo Therapeutics (NASDAQ:LXEO) with a $23 price target.
July 16, 2024 | 2:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Lexeo Therapeutics (NASDAQ:LXEO) with a $23 price target.
The reaffirmation of a Buy rating and a $23 price target by Chardan Capital is likely to positively impact Lexeo Therapeutics' stock price in the short term as it reinforces investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100